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Dear Editor,
Refractory agitation in infants is fre-
quently met at the pediatric intensive
care unit (PICU) [1]. Finding the right
sedative to remedy this can be chal-
lenging, particularly as previous
research has shown that agitation in
critically ill children may also be a
marker for pediatric delirium (PD)
[1].
Over the last 2 years, four very
young critically ill infants (two girls,
two boys; age range 7–14 months;
mechanically ventilated and receiving
analgosedation according to interna-
tional guidelines) presented with
refractory agitation. Description of
the context and diagnostic approach
in our unit can be found in previous
publications [1]. Two of the four
children received alimemazine in
order to remedy agitation that was
present in spite of adequate analg-
osedation; however, agitation
worsened. In the two other infants,
analgosedative medication was being
tapered off slowly when the children
developed agitation; despite rein-
statement of analgosedative
medication at its original dose or even
higher, agitation continued.
Although the Diagnostic and
Statistical Manual, fourth edition,
text revision (DSM-IV-TR) states that
cognitive change must be observed in
order to diagnose delirium, it has
been argued that refractory agita-
tion—as observed in these four
infants, after exclusion of other logi-
cal explanations—may be more
usefully considered as an expression
of PD [1, 2], which requires a dif-
ferent approach.
Delirium superimposed on with-
drawal may present as an excess in
the number, intensity, duration, and/
or responsiveness of the symptoms
normally associated with withdrawal
[2]. In the ﬁrst two children, sedative
medication may have induced PD
through anticholinergic mechanisms
(see below). In the other two children,
PD was superimposed on withdrawal
symptoms, as evidenced by nonre-
sponse to reinstatement of the original
sedative.
A recent consensus guideline on
sedation and analgesia in critically ill
children suggested that promethazine
or alimemazine (trimeprazine), both
H1-receptor antagonists, may be
considered for sedation [3]. However,
these medications are characterized
not only by sedation but also by
strong anticholinergic side-effects,
which may provoke agitation rather
than sedation in children, given that
cholinergic and dopaminergic
neurotransmission is linked to delir-
ium pathophysiology through,
respectively, hypocholinergic and/or
hyperdopaminergic states [4]. Thus,
H1-antagonists with their strong
anticholinergic and weak D2-block-
ing effects may kindle and aggravate
refractory agitation. Haloperidol,
however, with its weak anticholiner-
gic and strong D2-blocking effects,
may constitute a more effective
treatment [5, 6].
Haloperidol is a well-studied drug
with few side-effects and has been
successfully used for agitation in
young children [5, 6]. Haloperidol
and alimemazine both have low
risks of cardiac side-effects—ali-
memazine may carry a higher risk—
and rarely may induce malignant
neuroleptic syndrome. The four
children were successfully treated
with haloperidol intravenously
according to a minimal treatment
schedule (Table 1).
An empirical approach of steadily
titrating and close monitoring is
advocated in order to ﬁnd the right
dosage, maneuvering between clini-
cal response and side-effects. One
patient developed an intermittent
oculogyric crisis that was success-
fully treated with 50 lg/kg
biperiden i.v.
We conclude that refractory agita-
tion at the PICU may be a marker of
underlying PD, and that haloperidol
rather than an H1-receptor antagonist
may give satisfactory results.
Table 1 Minimal intravenous haloperidol dosage scheme for delirium in pediatric patients
Age
(years)
Weight
(kg)
Loading dose
(mg IV)
Haloperidol starting
dosage (mg/kg/24 h i.v.)
0–1 3.5–10 0.05 0.01
1–3 10–15 0.15 0.025
3–18 [15 0.25 0.05
Maximal haloperidol dosage in adults is approximately 5 mg/24 h i.v.
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